

# Eamonn M M Quigley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9169088/publications.pdf>

Version: 2024-02-01

207  
papers

17,343  
citations

26630

56  
h-index

14208

128  
g-index

233  
all docs

233  
docs citations

233  
times ranked

12226  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. <i>Gastroenterology</i> , 2005, 128, 541-551.	1.3	1,276
2	Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. <i>Gastroenterology</i> , 2021, 160, 99-114.e3.	1.3	913
3	An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. <i>Gut</i> , 2012, 61, 997-1006.	12.1	742
4	Efficacy of an Encapsulated Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2006, 101, 1581-1590.	0.4	739
5	The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 649-667.	17.8	701
6	Irritable bowel syndrome. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16014.	30.5	674
7	Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1547-1561.	0.4	595
8	The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. <i>Gut</i> , 2010, 59, 325-332.	12.1	588
9	Hypothalamic-Pituitary-Gut Axis Dysregulation in Irritable Bowel Syndrome: Plasma Cytokines as a Potential Biomarker?. <i>Gastroenterology</i> , 2006, 130, 304-311.	1.3	544
10	Microbiota-Brain-Gut Axis and Neurodegenerative Diseases. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 94.	4.2	513
11	American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. <i>American Journal of Gastroenterology</i> , 2014, 109, S2-S26.	0.4	503
12	Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. <i>Gut</i> , 2009, 58, 367-378.	12.1	486
13	Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2008, 337, a2313-a2313.	2.3	454
14	Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1044-1060.	3.7	423
15	<i>Bifidobacterium infantis</i> 35624 modulates host inflammatory processes beyond the gut. <i>Gut Microbes</i> , 2013, 4, 325-339.	9.8	342
16	Gastrointestinal symptoms in Parkinson's disease. <i>Movement Disorders</i> , 1991, 6, 151-156.	3.9	338
17	Effect of Antidepressants and Psychological Therapies, Including Hypnotherapy, in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1350-1365.	0.4	335
18	Title is missing!. <i>Antonie Van Leeuwenhoek</i> , 1999, 76, 279-292.	1.7	320

#	ARTICLE	IF	CITATIONS
19	Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12-week, randomized, double-blind, placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 315-328.	3.7	312
20	Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2019, 114, 21-39.	0.4	303
21	A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPS Diet in Treating Symptoms of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2018, 113, 1290-1300.	0.4	269
22	American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2018, 113, 1-18.	0.4	262
23	The Effect of Fiber Supplementation on Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1367-1374.	0.4	258
24	<i>Bifidobacterium infantis</i> 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. <i>Gut</i> , 2012, 61, 354-366.	12.1	242
25	Systematic review: cardiovascular safety profile of 5-HT <sub>4</sub> agonists developed for gastrointestinal disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 745-767.	3.7	236
26	Prebiotics and Probiotics in Digestive Health. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 333-344.	4.4	215
27	Constipation in parkinson's disease: Objective assessment and response to psyllium. <i>Movement Disorders</i> , 1997, 12, 946-951.	3.9	190
28	Manipulation of the Microbiota for Treatment of IBS and IBD – Challenges and Controversies. <i>Gastroenterology</i> , 2014, 146, 1554-1563.	1.3	149
29	An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2009, 104, S8-S35.	0.4	140
30	Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. <i>Gut</i> , 2020, 69, 1441-1451.	12.1	137
31	Probiotics in Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 769-782.	2.2	131
32	Gastrointestinal symptoms in parkinson disease: 18-month follow-up study. <i>Movement Disorders</i> , 1993, 8, 83-86.	3.9	124
33	A Global Perspective on Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 356-366.	2.2	124
34	Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. <i>Gut</i> , 2020, 69, 74-82.	12.1	122
35	Defecatory function in Parkinson's disease: Response to apomorphine. <i>Annals of Neurology</i> , 1993, 33, 490-493.	5.3	120
36	Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. <i>Gastroenterology</i> , 2018, 155, 1753-1763.	1.3	119

#	ARTICLE	IF	CITATIONS
37	Antroduodenal manometry. <i>Digestive Diseases and Sciences</i> , 1992, 37, 20-28.	2.3	108
38	Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 117-131.	8.1	108
39	Portrait of an immunoregulatory bifidobacterium. <i>Gut Microbes</i> , 2012, 3, 261-266.	9.8	104
40	Fecal excretion of <i>Bifidobacterium infantis</i> 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. <i>Gut Microbes</i> , 2013, 4, 201-211.	9.8	99
41	Gut microbiome as a clinical tool in gastrointestinal disease management: are we there yet?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 315-320.	17.8	96
42	Cisapride: What can we learn from the rise and fall of a prokinetic?. <i>Journal of Digestive Diseases</i> , 2011, 12, 147-156.	1.5	87
43	AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. <i>Gastroenterology</i> , 2020, 159, 1526-1532.	1.3	84
44	The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastroesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 1503-1509.	3.7	83
45	The enteric microbiota in the pathogenesis and management of constipation. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 119-126.	2.4	81
46	Irritable bowel syndrome: The burden and unmet needs in Europe. <i>Digestive and Liver Disease</i> , 2006, 38, 717-723.	0.9	80
47	The Spectrum of Small Intestinal Bacterial Overgrowth (SIBO). <i>Current Gastroenterology Reports</i> , 2019, 21, 3.	2.5	79
48	Small intestinal bacterial overgrowth. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 141-146.	2.3	77
49	Irritable bowel syndrome: Role of food in pathogenesis and management. <i>Journal of Digestive Diseases</i> , 2009, 10, 237-246.	1.5	76
50	Prebiotics and Probiotics. <i>Nutrition in Clinical Practice</i> , 2012, 27, 195-200.	2.4	74
51	The Gut-Brain Axis and the Microbiome: Clues to Pathophysiology and Opportunities for Novel Management Strategies in Irritable Bowel Syndrome (IBS). <i>Journal of Clinical Medicine</i> , 2018, 7, 6.	2.4	73
52	Anorectal function in fluctuating (on-off) Parkinson's disease: Evaluation by combined anorectal manometry and electromyography. <i>Movement Disorders</i> , 1995, 10, 650-657.	3.9	72
53	Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2357-2372.	2.3	68
54	Efficacy of Prolonged Administration of Intravenous Erythromycin in an Ambulatory Setting as Treatment of Severe Gastroparesis: One Center's Experience. <i>Journal of Clinical Gastroenterology</i> , 1999, 28, 131-134.	2.2	64

#	ARTICLE	IF	CITATIONS
55	Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 199-212.	3.2	63
56	Anorectal manometry in the assessment of anorectal function in Parkinson's disease: A comparison with chronic idiopathic constipation. <i>Movement Disorders</i> , 1994, 9, 655-663.	3.9	61
57	Prucalopride: safety, efficacy and potential applications. <i>Therapeutic Advances in Gastroenterology</i> , 2012, 5, 23-30.	3.2	57
58	Review article: gastric emptying in functional gastrointestinal disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 56-60.	3.7	54
59	Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases?. <i>Chinese Journal of Digestive Diseases</i> , 2005, 6, 122-132.	1.0	54
60	The <sc>PAC</sc>-<sc>SYM</sc> questionnaire for chronic constipation: defining the minimal important difference. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1103-1111.	3.7	54
61	Probiotics in functional gastrointestinal disorders: what are the facts?. <i>Current Opinion in Pharmacology</i> , 2008, 8, 704-708.	3.5	53
62	The Effect of Dietary Intervention on Irritable Bowel Syndrome: A Systematic Review. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e107.	2.5	48
63	Review article: quality-of-life issues in gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 41-47.	3.7	45
64	The Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Chronic Idiopathic Constipation (BURDEN-CIC) Study: Results of an Online Questionnaire. <i>Advances in Therapy</i> , 2017, 34, 2661-2673.	2.9	45
65	Prokinetics in the Management of Functional Gastrointestinal Disorders. <i>Journal of Neurogastroenterology and Motility</i> , 2015, 21, 330-336.	2.4	41
66	Immune response in irritable bowel syndrome: A systematic review of systemic and mucosal inflammatory mediators. <i>Journal of Digestive Diseases</i> , 2016, 17, 572-581.	1.5	41
67	Lost microbes of COVID-19: <i>Bifidobacterium</i>, <i>Faecalibacterium</i> depletion and decreased microbiome diversity associated with SARS-CoV-2 infection severity. <i>BMJ Open Gastroenterology</i> , 2022, 9, e000871.	2.7	39
68	The probiotic <i>Bifidobacterium</i> in the management of Coronavirus: A theoretical basis. <i>International Journal of Immunopathology and Pharmacology</i> , 2020, 34, 205873842096130.	2.1	36
69	Recent advances in modulating the microbiome. <i>F1000Research</i> , 2020, 9, 46.	1.6	36
70	Definition, Pathogenesis, and Management of ThatâCursedâDyspepsia. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 467-479.	4.4	35
71	Prokinetics in the Management of Functional Gastrointestinal Disorders. <i>Current Gastroenterology Reports</i> , 2017, 19, 53.	2.5	33
72	Small Intestinal Bacterial Overgrowthâ€”Pathophysiology and Its Implications for Definition and Management. <i>Gastroenterology</i> , 2022, 163, 593-607.	1.3	33

#	ARTICLE	IF	CITATIONS
73	Factors That Influence Therapeutic Outcomes in Symptomatic Gastroesophageal Reflux Disease. <i>American Journal of Gastroenterology</i> , 2003, 98, S24-S30.	0.4	32
74	The "Con"™ case. The Rome Process and Functional Gastrointestinal Disorders: the barbarians are at the gate!. <i>Neurogastroenterology and Motility</i> , 2007, 19, 793-797.	3.0	31
75	Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm. <i>Indian Journal of Gastroenterology</i> , 2020, 39, 9-21.	1.4	29
76	Nutraceuticals as modulators of gut microbiota: Role in therapy. <i>British Journal of Pharmacology</i> , 2020, 177, 1351-1362.	5.4	28
77	Bile acid metabolism and biliary secretion in patients receiving orthotopic liver transplants: Differing effects of cyclosporine and FK 506. <i>Hepatology</i> , 1994, 19, 1381-1389.	7.3	27
78	Plausibility criteria for putative pathophysiological mechanisms in functional gastrointestinal disorders: a consensus of experts. <i>Gut</i> , 2018, 67, 1425-1433.	12.1	27
79	Probiotics in Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, S60-S64.	2.2	26
80	Antibiotics and probiotics in inflammatory bowel disease: when to use them?. <i>Frontline Gastroenterology</i> , 2020, 11, 62-69.	1.8	26
81	An evaluation of an ambulatory manometry system in assessment of antroduodenal motor activity. <i>Digestive Diseases and Sciences</i> , 1996, 41, 1531-1537.	2.3	24
82	From comic relief to real understanding; how intestinal gas causes symptoms. <i>Gut</i> , 2003, 52, 1659-1661.	12.1	24
83	The role of the microbiome and the use of probiotics in gastrointestinal disorders in adults in the Asia-Pacific region -background and recommendations of a regional consensus meeting. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 57-69.	2.8	24
84	Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Irritable Bowel Syndrome with Constipation (BURDEN IBS-C) Study: Results of an Online Questionnaire. <i>Advances in Therapy</i> , 2018, 35, 967-980.	2.9	24
85	Reply to: Postbiotics "when simplification fails to clarify. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 827-828.	17.8	24
86	Bugs on the brain; brain in the gut"seeking explanations for common gastrointestinal symptoms. <i>Irish Journal of Medical Science</i> , 2013, 182, 1-6.	1.5	23
87	The Metabolic Role of the Microbiome: Implications for NAFLD and the Metabolic Syndrome. <i>Seminars in Liver Disease</i> , 2016, 36, 312-316.	3.6	21
88	A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation. <i>Current Medical Research and Opinion</i> , 2013, 29, 149-160.	1.9	19
89	Diet and irritable bowel syndrome. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 166-171.	2.3	19
90	Effects of the vibrating capsule on colonic circadian rhythm and bowel symptoms in chronic idiopathic constipation. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13890.	3.0	19

#	ARTICLE	IF	CITATIONS
91	New developments in the pathophysiology of gastro-oesophageal reflux disease (GERD): implications for patient management. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 43-51.	3.7	18
92	Probiotics in Gastrointestinal Disorders. <i>Hospital Practice</i> (1995), 2010, 38, 122-129.	1.0	18
93	THE INTESTINAL MICROBIOTA AND THE ROLE OF PROBIOTICS IN IRRITABLE BOWEL SYNDROME: a review. <i>Arquivos De Gastroenterologia</i> , 2015, 52, 331-338.	0.8	18
94	Systematic review with meta-analysis: cholecystectomy for biliary dyskinesia—what can the gallbladder ejection fraction tell us?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 654-663.	3.7	18
95	Critical care dysmotility: abnormal foregut motor function in the ICU/ITU patient. <i>Gut</i> , 2005, 54, 1351-1352.	12.1	17
96	Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14070.	3.0	17
97	Chronic intestinal pseudo-obstruction. <i>Current Treatment Options in Gastroenterology</i> , 1999, 2, 239-250.	0.8	16
98	Acute intestinal pseudo-obstruction. <i>Current Treatment Options in Gastroenterology</i> , 2000, 3, 273-285.	0.8	16
99	The diagnosis of small intestinal bacterial overgrowth: Two steps forward, one step backwards?. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13494.	3.0	16
100	The clinical pharmacology of motility disorders: The perils (and pearls) of prokinesia. <i>Gastroenterology</i> , 1994, 106, 1112-1114.	1.3	15
101	Symptoms and gastric function in dyspepsia — goodbye to gastroparesis?. <i>Neurogastroenterology and Motility</i> , 1996, 8, 273-275.	3.0	15
102	Carriage of <i>Clostridium difficile</i> in outpatients with irritable bowel syndrome. <i>Journal of Medical Microbiology</i> , 2012, 61, 1290-1294.	1.8	15
103	Basic Definitions and Concepts: Organization of the Gut Microbiome. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 1-8.	2.2	15
104	Pharmacotherapy of gastroparesis. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 881-887.	1.8	14
105	What is the evidence for the use of probiotics in functional disorders?. <i>Current Gastroenterology Reports</i> , 2008, 10, 379-384.	2.5	14
106	The Future of Probiotics for Disorders of the Brain-Gut Axis. <i>Advances in Experimental Medicine and Biology</i> , 2014, 817, 417-432.	1.6	14
107	The Microbiome and the Liver: The Basics. <i>Seminars in Liver Disease</i> , 2016, 36, 299-305.	3.6	13
108	Primary Biliary Cirrhosis and the Microbiome. <i>Seminars in Liver Disease</i> , 2016, 36, 349-353.	3.6	13

#	ARTICLE	IF	CITATIONS
109	Advancing treatment options for chronic idiopathic constipation. Expert Opinion on Pharmacotherapy, 2016, 17, 501-511.	1.8	13
110	Therapeutic implications of the gastrointestinal microbiome. Current Opinion in Pharmacology, 2018, 38, 90-96.	3.5	13
111	Pharmabiotic Manipulation of the Microbiota in Gastrointestinal Disorders: A Clinical Perspective. Journal of Neurogastroenterology and Motility, 2018, 24, 355-366.	2.4	13
112	Epigenetics: filling in the 'heritability gap' and identifying gene-environment interactions in ulcerative colitis. Genome Medicine, 2012, 4, 72.	8.2	12
113	Brain Foggiess™ and D-Lactic Acidosis: Probiotics Are Not the Cause. Clinical and Translational Gastroenterology, 2018, 9, e187.	2.5	12
114	Clinical Trials of Probiotics in Patients With Irritable Bowel Syndrome: Some Points to Consider. Journal of Neurogastroenterology and Motility, 2022, 28, 204-211.	2.4	11
115	Transdermal delivery of erythromycin lactobionate-implications for the therapy of gastroparesis. Alimentary Pharmacology and Therapeutics, 1997, 11, 589-592.	3.7	10
116	Commentary: synbiotics and gut microbiota in older people - a microbial guide to healthy ageing. Alimentary Pharmacology and Therapeutics, 2013, 38, 1141-1142.	3.7	10
117	Glucagon, stress, and portal hypertension. Digestive Diseases and Sciences, 1995, 40, 1816-1823.	2.3	9
118	Motility, heartburn and dyspepsia. Alimentary Pharmacology and Therapeutics, 1997, 11, 41-50.	3.7	9
119	Prebiotics for irritable bowel syndrome. Expert Review of Gastroenterology and Hepatology, 2009, 3, 487-492.	3.0	8
120	Constipation, IBs and the 5-HT4 Receptor: What Role for Prucalopride?. Clinical Medicine Gastroenterology, 2010, 3, CGast.S4136.	0.2	8
121	Bacteria, genetics and irritable bowel syndrome. Expert Review of Gastroenterology and Hepatology, 2010, 4, 271-276.	3.0	8
122	CT-based estimation of intracavitary gas volumes using threshold-based segmentation: In vitro study to determine the optimal threshold range. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 289-294.	1.8	8
123	Emerging treatments for chronic constipation. Expert Opinion on Emerging Drugs, 2013, 18, 365-373.	2.4	8
124	Prevalence of cardiovascular risk factors in a nationally representative adult population with inflammatory bowel disease without atherosclerotic cardiovascular disease. American Journal of Preventive Cardiology, 2021, 6, 100171.	3.0	8
125	Gastric Compliance and Motility in the Portal Hypertensive Rat. Journal of Investigative Surgery, 1992, 5, 109-114.	1.3	7
126	Home Parenteral Nutrition: Complications, Survival, Costs and Quality of Life. , 0, , 130-141.		7



#	ARTICLE	IF	CITATIONS
127	Editorial: differentiating chronic idiopathic constipation from constipationâ€predominant irritable bowel syndrome â€possible and important?. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1299-1299.	3.7	7
128	Symptoms and the small intestinal microbiome â€the unknown explored. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 457-458.	17.8	7
129	Peppermint Oil in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2020, 159, 395-396.	1.3	7
130	Probiotics, prebiotics & synbiotics in small intestinal bacterial overgrowth: opening up a new therapeutic horizon!. <i>Indian Journal of Medical Research</i> , 2014, 140, 582-4.	1.0	7
131	Aerophagia and intestinal gas. <i>Current Treatment Options in Gastroenterology</i> , 2002, 5, 259-265.	0.8	6
132	Why do we have so few effective drugs for irritable bowel syndrome? A European perspective. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2005, 2, 436-437.	1.7	6
133	Intestinal Adaptation. , 0, , 45-54.		6
134	A Critical Review of the Current Clinical Landscape of Gastroparesis. <i>Gastroenterology and Hepatology</i> , 2018, 14, 140-145.	0.1	6
135	Pharmacoeconomic study of chronic constipation in a secondary care centre. <i>Irish Journal of Medical Science</i> , 2015, 184, 863-870.	1.5	5
136	The alternative serotonin transporter promoter P2 impacts gene function in females with irritable bowel syndrome. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 8047-8061.	3.6	5
137	Intestinal Failure-Associated Liver Disease. , 0, , 191-200.		4
138	The Enteric Flora in Intestinal Failure. , 0, , 167-184.		4
139	Barrett's esophagus: clinical features, obesity, and imaging. <i>Annals of the New York Academy of Sciences</i> , 2011, 1232, 36-52.	3.8	4
140	The Microbiome: What Will the Future Hold?. <i>Seminars in Liver Disease</i> , 2016, 36, 354-359.	3.6	4
141	Antroduodenal manometry. <i>Digestive Diseases and Sciences</i> , 1992, 37, 1305-1308.	2.3	3
142	Small intestinal transplantation. <i>Current Gastroenterology Reports</i> , 2001, 3, 408-411.	2.5	3
143	Editorial: food for thoughtâ€the lowâ€FODMAP diet and IBS in perspective. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 206-207.	3.7	3
144	Autoimmune liver disease and the enteric microbiome. <i>AIMS Microbiology</i> , 2018, 4, 334-346.	2.2	3

#	ARTICLE	IF	CITATIONS
145	Vascular Access, Including Complications. , 0, , 142-150.		2
146	Enteral Support for Children with Intestinal Failure. , 0, , 151-159.		2
147	Psychiatric Issues in the Assessment of the Patient with Intestinal Failure. , 0, , 201-205.		2
148	Editorial: PARs for the Course: Roles of Proteases and PAR Receptors in Subtly Inflamed Irritable Bowel Syndrome. American Journal of Gastroenterology, 2013, 108, 1644-1646.	0.4	2
149	Commentary: probing probiotics in cirrhosis â€” a template for future studies?. Alimentary Pharmacology and Therapeutics, 2014, 39, 1334-1335.	3.7	2
150	The past 10 years of gastroenterology and hepatologyâ€™ reflections and predictions. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 692-700.	17.8	2
151	What can we learn from other clinical settings on the influence of the gut microbiome on the brain?. Clinical Liver Disease, 2017, 9, 52-54.	2.1	2
152	Probiotics and Irritable Bowel Syndrome. Bioscience and Microflora, 2009, 28, 119-124.	0.5	2
153	Intestinal motility: Normal and disturbed patterns. Chinese Journal of Digestive Diseases, 2003, 4, 1-4.	1.0	1
154	Gastrointestinal dysfunction in neurological disease: a report of an interdisciplinary international symposium. Neurogastroenterology and Motility, 2008, 6, 55-57.	3.0	1
155	Infections in Small Bowel Transplant Recipients. , 0, , 297-304.		1
156	The Use of Enteral Nutrition in the Adult with Intestinal Failure. , 0, , 160-166.		1
157	Management of Complex Fluid and Electrolyte Disturbances. , 0, , 185-190.		1
158	Isolated Small Bowel Transplantation and Combined Liver-Small Bowel Transplantation. , 0, , 254-261.		1
159	Preservation of the Intestine. , 0, , 275-282.		1
160	Immediate Postoperative Care of the Intestinal Transplant Recipient. , 0, , 283-289.		1
161	Financial, Economic and Insurance Issues Pertaining to Intestinal Transplantation: When is too much not enough?. , 0, , 363-377.		1
162	Inflammatory Bowel Disease and the Short Bowel Syndrome. , 0, , 99-106.		1

#	ARTICLE	IF	CITATIONS
163	Guidelines for Home Parenteral Nutrition Support in Chronic Intestinal Failure Patients. , 0, , 122-129.		1
164	Commentary: long-term lubiprostone for constipation predominant IBS. Alimentary Pharmacology and Therapeutics, 2012, 35, 962-963.	3.7	1
165	Editorial: allergy and recurrent abdominal pain of childhood/irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2015, 41, 229-229.	3.7	1
166	Editorial: diet, inflammation and irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2017, 45, 1278-1279.	3.7	1
167	Editorial: Lactobacillus GG for diarrhoea in children’s reports of its demise have been premature!. Alimentary Pharmacology and Therapeutics, 2019, 49, 1533-1534.	3.7	1
168	Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS. Authors’ reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 1254-1255.	3.7	1
169	The Dilemma of Persistent Irritable Bowel Syndrome Symptoms in Patients with Quiescent Inflammatory Bowel Disease. Gastroenterology Clinics of North America, 2021, 50, 689-711.	2.2	1
170	Editorial: the microbiome, aspirin and colorectal cancer. Alimentary Pharmacology and Therapeutics, 2020, 52, 1740-1741.	3.7	1
171	Esophageal stricture: Not your usual culprit?. Gastroenterology, 2021, , .	1.3	1
172	Editorial: risky business. What do sufferers' perceptions of risk from interventions for irritable bowel syndrome really mean?. Alimentary Pharmacology and Therapeutics, 2022, 55, 1218-1219.	3.7	1
173	Development and Evaluation in an ex vivo Rat Model of a Technique for the Endoscopic Assessment of Mucosal Defense in Man. Scandinavian Journal of Gastroenterology, 1991, 26, 353-360.	1.5	0
174	Antroduodenal manometry. Digestive Diseases and Sciences, 1992, 37, 1927-1927.	2.3	0
175	Dysphagia and diffuse oesophageal spasm as the presenting manifestation of the glucagonoma-neuropathy syndrome. Ecological Management and Restoration, 1995, , .	0.4	0
176	Letters to the editor. Muscle and Nerve, 1996, 19, 109-114.	2.2	0
177	Is there a future for a national scientific medical journal in Ireland?. Irish Journal of Medical Science, 2000, 169, 12-12.	1.5	0
178	Assessment of Intestinal Failure Patients. , 0, , 115-121.		0
179	Intestinal Failure: Definitions and Classifications. , 0, , 55-65.		0
180	Immunology of the Small Intestine. , 0, , 33-44.		0

#	ARTICLE	IF	CITATIONS
181	Basic Physiology of Motility, Absorption and Secretion. , 0 , 20-32.		0
182	The History of Intestinal Failure and Transplantation. , 0 , 1-10.		0
183	Intestinal Failure Related to Bariatric Surgery. , 0 , 93-98.		0
184	Motility Disorders. , 0 , 107-113.		0
185	Munchausen Syndrome by Proxy. , 0 , 206-211.		0
186	The Role of Humoral Factors in Intestinal Adaptation. , 0 , 223-228.		0
187	Autologous Reconstruction of the GI Tract. , 0 , 229-241.		0
188	Living Donor Intestinal Transplantation. , 0 , 262-269.		0
189	Isolated Liver Transplantation for Intestinal Failure-Associated Liver Disease. , 0 , 270-274.		0
190	Surgical Complications of Intestinal Transplantation. , 0 , 290-296.		0
191	Immunosuppression after Intestinal Transplantation. , 0 , 305-313.		0
192	Immunology of Intestinal Allograft Rejection. , 0 , 314-321.		0
193	Histopathology of Intestinal Transplantation. , 0 , 322-330.		0
194	Long-Term Management of Intestinal Transplant Recipients. , 0 , 331-341.		0
195	Management of Posttransplant Lymphoproliferative Disease. , 0 , 342-348.		0
196	Results of Intestinal Transplantation. , 0 , 349-356.		0
197	Psychosocial Assessment and Management of the Transplant Patient/Family in Intestinal Transplantation. , 0 , 357-362.		0
198	Causes of Intestinal Failure in the Newborn. , 0 , 66-76.		0

#	ARTICLE	IF	CITATIONS
199	Congenital Enteropathies Causing Permanent Intestinal Failure. , 0 , 77-87.		0
200	Luminal Nutrient Factors in Intestinal Adaptation and their use in Therapy. , 0 , 213-222.		0
201	Causes of Intestinal Failure in the Adult. , 0 , 88-92.		0
202	Leadership in Medicine: Do We Need a New Approach?. American Journal of Gastroenterology, 2014, 109, 786-788.	0.4	0
203	Microbiome Modulation in Liver Disease. Clinical Liver Disease, 2019, 14, 149-151.	2.1	0
204	Commentary: faecal microbiota transplantationâ€™from home brew to holy grail. Alimentary Pharmacology and Therapeutics, 2020, 51, 208-209.	3.7	0
205	Low FODMAP (fermentable oligo-, di-, monosaccharides, and polyol) diet goes global. American Journal of Clinical Nutrition, 2021, 113, 1394-1395.	4.7	0
206	Highlights of the Updated Evidence-Based IBS Treatment Monograph. Gastroenterology and Hepatology, 2018, 14, 665-667.	0.1	0
207	Irritable bowel syndrome in celiac disease - relationships to celiac disease antibodies and levels of pro-inflammatory cytokines. Revista De Gastroenterologia Del Peru: Organo Oficial De La Sociedad De Gastroenterologia Del Peru, 2020, 40, 127-135.	0.2	0